invivodata’s DiaryPRO Captures Primary Efficacy Data for Patanase® Nasal Spray
invivodata’s DiaryPRO captures primary efficacy data for Patanase, and Alcon receives FDA approval to market Patanase in the United States.
Pittsburgh, PA-May 15, 2008-invivodata (www.invivodata.com), the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced that its eDiary solution, DiaryPRO®, captured some of the primary efficacy data that supported the recent U.S. Food and Drug Administration’s (FDA) approval of Alcon’s Patanase(Olopatadine Hydrochloride) Nasal Spray, indicated for the relief of the symptoms of seasonal allergic rhinitis in patients 12 years of age and older.
For Alcon’s Phase III program, invivodata designed and implemented an eDiary solution that complied with the FDA’s guidance on the use of patient reported outcomes (PROs) in clinical research. During a two-week trial, subjects with seasonal allergic rhinitis used DiaryPRO twice daily to record the frequency and severity of their nasal symptoms. The data captured on DiaryPRO helped Alcon demonstrate a significantly greater decrease in allergy symptoms among patients using Patanase compared with patients using a placebo nasal spray.
&ldquo'In studying Patanase for the relief of allergy symptoms, we needed an efficient and specific data collection method that was easy for patients and investigative site personnel to use,” said G. Michael Wall, senior director of pharmaceutical product development at Alcon. “invivodata met our tight enrollment timelines and delivered the scientific expertise and technology that were important to the success of this program.”
“This trial represents a common challenge in clinical research: getting the right data from patients at the right time,” said Doug Engfer, president and chief executive officer of invivodata. “We are thrilled to have worked with Alcon in its development of Patanase and support its efforts to provide much needed relief to the millions of patients suffering with allergic rhinitis.”
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
